No Data
No Data
No Data
Statistics on the proportion of mainland investors in the SmartHK Stock Connect program | July 23rd
Statistics of unusual proportion of Wise H.K. Connect | July 22, 2024.
Tigermed (03347.HK) spent 2.7083 million yuan to repurchase 0.05 million A shares on July 22.
On July 22, Gelunhui reported that Tigermed (03347.HK) will purchase 0.05 million A-shares, at a cost of 2.7083 million yuan, on July 22, 2024. The repurchase price is between 54.14 and 54.25 yuan per share.
Contract research organizations are generally increasing. Pharmaron (03759) rose 6.66%, and Orient Securities is expected to see marginal improvement in the sector.
Jingu Financial News| The concept of contract research organizations is rising across the board. As of the time of publication, Pharmaron (03759) rose 6.66%, Viva Biotech (01873) rose 5.05%, Tigermed (03347) rose 2.84%, and Wuxi Bio (02269) rose 2.77%. On the news side, Orient Securities stated that according to the latest data on the key indicators of the CRO industry's prosperity index, the global fund has basically stabilized, while the domestic investment and financing side is still tight; however, the enthusiasm for research and development has not diminished, and the IND and new clinical trials are still at a high level. The bank believes that the CXO sector, after experiencing double killings in performance and valuation, is expected to welcome a
Unusual event report | CRO concept stocks rose collectively, with the top companies signing new orders with double-digit growth in amount, and the sector is expected to see marginal improvement.
CRO concept stocks collectively rose. As of press time, Pharmaron (03759) rose 7.23% to HKD 9.34, Viva Biotech (01873) rose 3.03% to HKD 0.51, and Tigermed (03347) rose 2.84% to HKD 30.75.
On July 19th, Tigermed (03347.HK) spent 2.7324 million yuan to repurchase 0.0525 million A shares.
On July 19, Gelunhui reported that Tigermed (03347.HK) spent 2.7324 million yuan to repurchase 0.0525 million A-shares on July 19, 2024, at a repurchase price of 51.97-52.15 yuan per share.
Hong Kong stocks saw unusual activity as CRO concept stocks rose collectively. With the nearing interest rate cut by the Federal Reserve and frequent bullish policies, the sector is expected to usher in marginal improvements.
Concept stocks of CRO have collectively risen. As of press time, Tigermed (03347) rose 4.75%, to HKD 28.65; Genscript Bio (01548) rose 4.66%, to HKD 13.02.
No Data